Fig. 2 | Leukemia

Fig. 2

From: Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Fig. 2

Inositide-Specific mutated genes according to the SIFT score in MDS patients at baseline, at the 4th cycle (T4) and at the 8th cycle (T8) of azacitidine and lenalidomide therapy. Venn diagram showing the global number of mutated genes, divided according to the SIFT score, in: a all patients analyzed, b Good Responders, c Transient Responders, d Non Responders. The bottom part of the Figure shows the genes acquiring specific mutations during the therapy in: e all patients analyzed (common T4 and T8, n = 1), f GR patients (common T4 and T8, n = 3), g TR patients (common T4 and T8, n = 5; T8 only, n = 6), h NR patients (T8 only, n = 6), clustered according to the SIFT score: gray squares indicate no mutation, green to red squares indicate a lower to higher probability of impaired protein function due to mutation

Back to article page